H2拮抗薬の世界市場レポート2025年

H2拮抗薬市場規模は、今後数年間で力強い成長が見込まれます。2029年には複合年間成長率（CAGR）6.6％で236億3,000万米ドルに成長します。予測期間の成長は、費用対効果の高い酸減少薬に対する需要の増加、現代人のライフスタイルに関連した胃腸障害の増加、世界の高齢化、併用療法の継続的研究、動物医療における用途の拡大、健康とウェルネスに対する消費者の意識の高まりなどに起因すると考えられます。予測期間中に予想される主な動向には、ドラッグデリバリーシステムの革新、医薬品開発における人工知能（AI）の統合、標的薬物送達のためのナノテクノロジーの応用、高度な製剤によるバイオアベイラビリティの向上、患者追跡のためのデジタルヘルスプラットフォームの利用、個別化医療戦略の採用などがあります。

胃腸疾患の有病率の上昇は、今後数年間におけるH2拮抗薬市場の成長を促進すると予想されます。胃腸（GI）疾患は、食道、胃、腸、肝臓、膵臓、胆嚢などの消化器官に影響を及ぼす病状です。胃酸の過剰分泌や消化器系の炎症につながる食生活の乱れが主な原因となっています。H2拮抗薬は、胃酸の分泌を減少させ、胃酸逆流や潰瘍などの疾患の治療に効果的であるため、これらの疾患の管理に役立ちます。迅速な症状緩和と長期的な消化器系の健康サポートにより、患者の幸福度を向上させる。例えば、2024年3月、スイスに本部を置く国連の専門機関である世界保健機関（WHO）は、下痢性疾患は毎年約17億人の患者を引き起こし、5歳未満の子どもの約44万3,832人の死亡に加え、5歳から9歳の子どもの5万8,851人の死亡の原因となっていると報告しました。このように、胃腸疾患の罹患率の増加がH2拮抗薬市場の拡大に拍車をかけています。

ヘルスケア支出の増加は、今後数年間のH2拮抗薬市場の成長を促進すると予想されます。ヘルスケア支出には、医療サービス、治療、インフラストラクチャー、研究、健康成果の向上や維持を目的とした公衆衛生プログラムに対する財政支出の総額が含まれます。ヘルスケア支出の増加は、主に継続的な治療と管理を必要とする慢性疾患の蔓延によるもので、それによって長期的な医療費が増大します。このような支出の増加は、先進的な治療法や医薬品へのアクセスを促進することにより、H2拮抗薬市場を支えています。また、研究開発努力も促進され、製剤の改善や患者ケアの向上につながります。例えば、2024年12月、米国の連邦政府機関であるメディケア・メディケイド・サービスセンター（CMS）は、2023年の国民医療費（NHE）が7.5％増の4兆9,000億米ドルに達し、国内総生産（GDP）の17.6％を占めると報告しました。さらに、2023年から2032年にかけて、NHEは年平均5.6%で成長し、GDPに占めるヘルスケアの割合は2022年の17.3%から2032年には19.7%に増加すると予測されています。したがって、ヘルスケア支出の増加がH2拮抗薬市場の拡大に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のH2拮抗薬：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のH2拮抗薬市場：成長率分析
• 世界のH2拮抗薬市場の実績：規模と成長, 2019-2024
• 世界のH2拮抗薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界のH2拮抗薬：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界のH2拮抗薬市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 処方箋H2拮抗薬
• 市販薬H2拮抗薬
• 世界のH2拮抗薬市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 胃食道逆流症（GERD）
• 消化性潰瘍
• ゾリンジャー・エリソン症候群
• その他の適応症
• 世界のH2拮抗薬市場剤形別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タブレット
• カプセル
• 注射液
• 液体製剤
• 世界のH2拮抗薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小売薬局
• 病院薬局
• オンライン薬局
• ドラッグストア
• 世界のH2拮抗薬市場処方H2拮抗薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 胃食道逆流症（GERD）
• 消化性潰瘍
• ゾリンジャー・エリソン症候群
• 世界のH2拮抗薬市場市販のH2拮抗薬（OTC）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 胸焼け
• 時々胃酸逆流が起こる
• 消化不良

第7章 地域別・国別分析

• 世界のH2拮抗薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のH2拮抗薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• H2拮抗薬市場：競合情勢
• H2拮抗薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis International AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline plc
• Eli Lilly and Company
• Teva Pharmaceutical Industries Limited
• Boehringer Ingelheim International GmbH
• Sun Pharmaceutical Industries Limited
• Apotex Inc.
• Dr. Reddy's Laboratories Limited
• Apex Biotechnology Corporation
• Ajanta Pharma Limited
• Medochemie Ltd.
• Torrent Pharmaceuticals Limited
• Phathom Pharmaceuticals Inc.
• Tocris Bioscience
• Cadila Healthcare Limited
• Modi Lifecare Industries Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• H2拮抗薬市場2029：新たな機会を提供する国
• H2拮抗薬市場2029：新たな機会を提供するセグメント
• H2拮抗薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

H2 antagonists are a class of medications that block H2 receptors located in the lining of the stomach. By inhibiting these receptors, they reduce the production of stomach acid, which aids in healing and alleviates symptoms associated with excessive acid. These medications are widely used for treating ulcers and are available in both prescription and over-the-counter formats, making them easily accessible to patients.

The primary types of H2 antagonists include prescription and over-the-counter variants. Prescription H2 antagonists are medications that require a doctor's prescription and function to decrease the amount of acid the stomach produces. They are prescribed for several conditions, such as gastroesophageal reflux disease (GERD), peptic ulcer disease, Zollinger-Ellison syndrome, and others. These drugs come in various dosage forms, including tablets, capsules, liquid solutions, and injectable formulations, and are distributed through retail pharmacies, hospital pharmacies, online platforms, and drugstores.

The H2 antagonists market research report is one of a series of new reports from The Business Research Company that provides H2 antagonists market statistics, including H2 antagonists industry global market size, regional shares, competitors with an H2 antagonists market share, H2 antagonists market segments, market trends and opportunities, and any further data you may need to thrive in the H2 antagonists industry. This H2 antagonists market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The H2 antagonists market size has grown strongly in recent years. It will grow from $17.14 billion in 2024 to $18.32 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth during the historic period can be attributed to the rising prevalence of acid-related disorders, an expanding geriatric population, heightened awareness of gastrointestinal health, cost-effectiveness compared to proton pump inhibitors, a growing number of stress-induced ulcers, and increased demand for non-invasive treatment alternatives

The H2 antagonists market size is expected to see strong growth in the next few years. It will grow to $23.63 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to the increasing demand for cost-effective acid-reducing medications, a rise in gastrointestinal disorders linked to modern lifestyles, a globally aging population, continued research into combination therapies, expanding applications in veterinary medicine, and growing consumer awareness of health and wellness. Key trends expected during the forecast period include innovations in drug delivery systems, the integration of artificial intelligence (AI) in drug development, the application of nanotechnology for targeted drug delivery, improved bioavailability through advanced formulations, the use of digital health platforms for patient tracking, and the adoption of personalized medicine strategies.

The rising prevalence of gastrointestinal disorders is anticipated to drive the growth of the H2 antagonists market in the coming years. Gastrointestinal (GI) disorders are medical conditions that affect the digestive organs, including the esophagus, stomach, intestines, liver, pancreas, and gallbladder. This growing prevalence is largely attributed to poor dietary habits, which can lead to excessive stomach acid production and irritation of the digestive system. H2 antagonists aid in managing these conditions by decreasing the production of stomach acid, making them effective in treating ailments such as acid reflux and ulcers. They improve patient well-being by providing rapid symptom relief and supporting long-term digestive health. For example, in March 2024, the World Health Organization (WHO), a specialized agency of the United Nations based in Switzerland, reported that diarrheal diseases cause around 1.7 billion cases each year and are responsible for approximately 443,832 deaths among children under the age of five, in addition to 50,851 deaths among children aged five to nine. Thus, the growing incidence of gastrointestinal disorders is fueling the expansion of the H2 antagonists market.

The rising healthcare expenditure is expected to fuel the growth of the H2 antagonists market in the coming years. Healthcare expenditure encompasses the total financial outlay on medical services, treatments, infrastructure, research, and public health programs aimed at enhancing or maintaining health outcomes. The increase in healthcare spending is primarily driven by the growing prevalence of chronic diseases, which require continuous treatment and management, thereby escalating long-term medical costs. This heightened expenditure supports the H2 antagonists market by facilitating greater access to advanced therapies and medications. It also promotes research and development efforts, resulting in improved drug formulations and enhanced patient care. For instance, in December 2024, the Centers for Medicare and Medicaid Services (CMS), a U.S.-based federal agency, reported that national health expenditures (NHE) rose by 7.5% to reach $4.9 trillion in 2023, representing 17.6% of the gross domestic product (GDP). Furthermore, between 2023 and 2032, NHE is projected to grow at an average annual rate of 5.6%, increasing the healthcare share of GDP from 17.3% in 2022 to 19.7% in 2032. Therefore, the rise in healthcare expenditure is contributing to the expansion of the H2 antagonists market.

Leading companies in the H2 antagonists market are concentrating on developing therapeutic strategies, such as generic formulations, to boost treatment effectiveness, enhance patient adherence, and prolong product lifecycles. A generic formulation is a pharmaceutical product that matches a brand-name drug in terms of dosage, strength, and method of administration. For example, in August 2022, Amneal Pharmaceuticals Inc., a U.S.-based pharmaceutical company, received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for famotidine oral suspension (40 mg/5 mL), a liquid oral H2 antagonist used for treating ulcers and gastroesophageal reflux disease (GERD). It is marketed under the reference brand Pepcid and provides a cost-effective solution for patients needing acid suppression therapy, serving as a valuable alternative in the treatment of acid reflux and ulcer-related conditions.

Major players in the h2 antagonists market are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis International AG, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Apotex Inc., Dr. Reddy's Laboratories Limited, Apex Biotechnology Corporation, Ajanta Pharma Limited, Medochemie Ltd., Torrent Pharmaceuticals Limited, Phathom Pharmaceuticals Inc., Tocris Bioscience, Cadila Healthcare Limited, and Modi Lifecare Industries Limited.

North America was the largest region in the H2 receptor antagonists market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in H2 antagonists report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the H2 antagonists market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The H2 antagonists market consists of sales of ranitidine, famotidine, cimetidine, and nizatidine. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

H2 Antagonists Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on h2 antagonists market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for h2 antagonists ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The h2 antagonists market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Prescription H2 Antagonists; Over-The-Counter H2 Antagonists
• 2) By Indication: Gastroesophageal Reflux Disease (GERD); Peptic Ulcer Disease; Zollinger-Ellison Syndrome; Other Indications
• 3) By Dosage Form: Tablets; Capsules; Injectable Solutions; Liquid Formulations
• 4) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Pharmacies; Drug Stores
• Subsegments:
• 1)By Prescription H2 Antagonists: Gastroesophageal Reflux Disease (GERD); Peptic Ulcers; Zollinger-Ellison Syndrome
• 2) By Over-The-Counter (OTC) H2 Antagonist: Heartburn; Occasional Acid Reflux; Indigestion
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; AbbVie Inc.; Bayer AG; Novartis International AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. H2 Antagonists Market Characteristics

3. H2 Antagonists Market Trends And Strategies

4. H2 Antagonists Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global H2 Antagonists Growth Analysis And Strategic Analysis Framework

• 5.1. Global H2 Antagonists PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global H2 Antagonists Market Growth Rate Analysis
• 5.4. Global H2 Antagonists Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global H2 Antagonists Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global H2 Antagonists Total Addressable Market (TAM)

6. H2 Antagonists Market Segmentation

• 6.1. Global H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prescription H2 Antagonists
• Over-The-Counter H2 Antagonists
• 6.2. Global H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gastroesophageal Reflux Disease (GERD)
• Peptic Ulcer Disease
• Zollinger-Ellison Syndrome
• Other Indications
• 6.3. Global H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets
• Capsules
• Injectable Solutions
• Liquid Formulations
• 6.4. Global H2 Antagonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• Drug Stores
• 6.5. Global H2 Antagonists Market, Sub-Segmentation Of Prescription H2 Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gastroesophageal Reflux Disease (GERD)
• Peptic Ulcers
• Zollinger-Ellison Syndrome
• 6.6. Global H2 Antagonists Market, Sub-Segmentation Of Over-The-Counter (OTC) H2 Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Heartburn
• Occasional Acid Reflux
• Indigestion

7. H2 Antagonists Market Regional And Country Analysis

• 7.1. Global H2 Antagonists Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global H2 Antagonists Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific H2 Antagonists Market

• 8.1. Asia-Pacific H2 Antagonists Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China H2 Antagonists Market

• 9.1. China H2 Antagonists Market Overview
• 9.2. China H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India H2 Antagonists Market

• 10.1. India H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan H2 Antagonists Market

• 11.1. Japan H2 Antagonists Market Overview
• 11.2. Japan H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia H2 Antagonists Market

• 12.1. Australia H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia H2 Antagonists Market

• 13.1. Indonesia H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea H2 Antagonists Market

• 14.1. South Korea H2 Antagonists Market Overview
• 14.2. South Korea H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe H2 Antagonists Market

• 15.1. Western Europe H2 Antagonists Market Overview
• 15.2. Western Europe H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK H2 Antagonists Market

• 16.1. UK H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany H2 Antagonists Market

• 17.1. Germany H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France H2 Antagonists Market

• 18.1. France H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy H2 Antagonists Market

• 19.1. Italy H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain H2 Antagonists Market

• 20.1. Spain H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe H2 Antagonists Market

• 21.1. Eastern Europe H2 Antagonists Market Overview
• 21.2. Eastern Europe H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia H2 Antagonists Market

• 22.1. Russia H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America H2 Antagonists Market

• 23.1. North America H2 Antagonists Market Overview
• 23.2. North America H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA H2 Antagonists Market

• 24.1. USA H2 Antagonists Market Overview
• 24.2. USA H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada H2 Antagonists Market

• 25.1. Canada H2 Antagonists Market Overview
• 25.2. Canada H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America H2 Antagonists Market

• 26.1. South America H2 Antagonists Market Overview
• 26.2. South America H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil H2 Antagonists Market

• 27.1. Brazil H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East H2 Antagonists Market

• 28.1. Middle East H2 Antagonists Market Overview
• 28.2. Middle East H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa H2 Antagonists Market

• 29.1. Africa H2 Antagonists Market Overview
• 29.2. Africa H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. H2 Antagonists Market Competitive Landscape And Company Profiles

• 30.1. H2 Antagonists Market Competitive Landscape
• 30.2. H2 Antagonists Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis

31. H2 Antagonists Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Eli Lilly and Company
• 31.3. Teva Pharmaceutical Industries Limited
• 31.4. Boehringer Ingelheim International GmbH
• 31.5. Sun Pharmaceutical Industries Limited
• 31.6. Apotex Inc.
• 31.7. Dr. Reddy's Laboratories Limited
• 31.8. Apex Biotechnology Corporation
• 31.9. Ajanta Pharma Limited
• 31.10. Medochemie Ltd.
• 31.11. Torrent Pharmaceuticals Limited
• 31.12. Phathom Pharmaceuticals Inc.
• 31.13. Tocris Bioscience
• 31.14. Cadila Healthcare Limited
• 31.15. Modi Lifecare Industries Limited

32. Global H2 Antagonists Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The H2 Antagonists Market

34. Recent Developments In The H2 Antagonists Market

35. H2 Antagonists Market High Potential Countries, Segments and Strategies

• 35.1 H2 Antagonists Market In 2029 - Countries Offering Most New Opportunities
• 35.2 H2 Antagonists Market In 2029 - Segments Offering Most New Opportunities
• 35.3 H2 Antagonists Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer